Amyloid Light Chain (AL) Amyloidosis is a condition where abnormal proteins, called amyloids, build up in tissues and organs, affecting their function. This study involves using Daratumumab, a medicine usually for blood cancers, combined with other drugs to understand its safety on the heart in people with AL amyloidosis. The study has two parts: one looks at heart safety, and the other focuses on how the medicine works in different racial groups.

Key Points:

• The study involves multiple visits and tests over time.
• Participants may receive compensation for their time and travel.
• There could be side effects, especially related to the heart.

To join, participants need to have certain health conditions, like heart involvement, and meet other health criteria. This study is not for those who have had certain treatments or other health issues like multiple myeloma. If you are eligible and considering joining, you should discuss it with your doctor to understand the benefits and risks.